Kala Bio (KALA) Receivables - Net (2019 - 2023)
Kala Bio (KALA) posted Receivables - Net of $668000.0 for Q1 2023, down 53.58% sequentially from $1.4 million in Q4 2022, and down 94.87% YoY from $13.0 million in Q1 2022.
Kala Bio (KALA) Receivables - Net (2019 - 2023) Analysis & Trends
Kala Bio has reported Receivables - Net for 5 years, with the latest figure at $668000.0 in Q1 2023.
- Quarterly Receivables - Net fell 94.87% year-over-year to $668000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $668000.0 (down 94.87% YoY) and the FY2022 annual result came in at $1.4 million, down 90.62% from the prior year.
- Receivables - Net retreated to $668000.0 in Q1 2023 per KALA's latest filing, from $1.4 million in the prior quarter.
- Over five years, Receivables - Net peaked at $15.3 million in Q4 2021 and troughed at $190000.0 in Q3 2022.
- A 5-year average of $8.0 million and a median of $7.5 million in 2020 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2021 and 2022: Receivables - Net surged 177.01% in 2021, then plunged 98.5% in 2022.
- Over 5 years, Receivables - Net stood at $11.6 million in 2019, then fell by 16.94% to $9.6 million in 2020, then soared by 59.78% to $15.3 million in 2021, then plunged by 90.62% to $1.4 million in 2022, then sank by 53.58% to $668000.0 in 2023.
- According to Business Quant data, Receivables - Net over the past three periods registered $668000.0, $1.4 million, and $190000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 668,000.00 |
| Mar 31, 2023 | 668,000.00 |
| Dec 31, 2022 | 1.44 Mn |
| Dec 31, 2022 | 1.44 Mn |
| Sep 30, 2022 | 190,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Jun 30, 2022 | 13.82 Mn |
| Jun 30, 2022 | 13.82 Mn |
| Mar 31, 2022 | 13.02 Mn |
| Mar 31, 2022 | 13.02 Mn |
| Dec 31, 2021 | 15.35 Mn |
| Dec 31, 2021 | 15.35 Mn |
| Sep 30, 2021 | 12.63 Mn |
| Sep 30, 2021 | 12.63 Mn |
| Jun 30, 2021 | 11.86 Mn |
| Jun 30, 2021 | 11.86 Mn |
| Mar 31, 2021 | 12.21 Mn |
| Mar 31, 2021 | 12.21 Mn |
| Dec 31, 2020 | 9.60 Mn |
| Dec 31, 2020 | 9.60 Mn |